Loading
Instead of separate screening programmes for a few cancers, assess every adult's overall cancer risk and offer blood tests, imaging and preventive treatment tuned to that risk, all inside one system that learns.
Screening today covers a handful of cancers with organ-specific programmes and reaches a fraction of eligible people. Multi-cancer early detection blood tests (NHS-Galleri, PATHFINDER 2) and polygenic, exposure and imaging-based risk models make a unified approach conceivable: every adult over 40 receives a risk profile, a personalised detection schedule, and where indicated interception (chemoprevention, vaccines, risk-reducing procedures), with all results feeding a national learning system that recalibrates the models. Overdiagnosis is controlled through molecular indolence classifiers and surveillance-first protocols.
Shares FAPI PET as the workup for MCED positives, Whole-body MRI, Early detection of cancer, Positive predictive value (PPV).
Shares PATHFINDER 2, NHS-Galleri, Stage shift, Galleri.
Shares PATHFINDER 2, NHS-Galleri, Positive predictive value (PPV), Stage shift.
Shares Early detection of cancer, Positive predictive value (PPV), Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, NHS-Galleri, Positive predictive value (PPV), Stage shift.
Shares PATHFINDER 2, Positive predictive value (PPV), Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, Early detection of cancer, NHS-Galleri, Multi-cancer early detection (MCED).
Shares NHS-Galleri, Stage shift, Galleri, Overdiagnosis and false alarms.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/